Physiomics ( (GB:PYC) ) just unveiled an announcement.
Physiomics plc has secured a new contract with a UK client to apply its modelling and simulation techniques in the development of a bifunctional antibody therapy targeting multiple solid tumor indications. This project, valued at £47,600, will utilize pharmacokinetic modelling to predict human PK and support the client’s first-in-human study. The contract signifies Physiomics’ progress in expanding its client base and enhancing its role in developing oncology therapies.
Spark’s Take on GB:PYC Stock
According to Spark, TipRanks’ AI Analyst, GB:PYC is a Underperform.
Physiomics faces substantial financial and technical challenges, reflected in declining revenues and bearish technical indicators. Recent corporate events provide some optimism for future growth, but current valuation issues and financial instability weigh heavily on its stock score.
To see Spark’s full report on GB:PYC stock, click here.
More about Physiomics
Physiomics plc is a leading company in mathematical modelling, data science, and biostatistics, specializing in supporting the development of new therapeutics and personalized medicine solutions. The company combines expertise in Modelling & Simulation, Biostatistics, Data Science, and Bioinformatics to help biotech and pharma companies optimize their drug development processes. Physiomics has informed the development of over 100 commercial projects and works with clients such as Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics, and CRUK.
YTD Price Performance: -48.00%
Average Trading Volume: 4,345,979
Technical Sentiment Signal: Buy
Current Market Cap: £1.18M
Find detailed analytics on PYC stock on TipRanks’ Stock Analysis page.